Perennial Allergic Rhinitis Market by Products (Anti-histamines, Decongestants, Steroids, and Others) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global perennial allergic rhinitis market size is anticipated to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising incidences of the disease and growing respiratory diseases. Moreover, the changing lifestyles such as alcohol consumption and smoking is also propelling the market in the coming years.

Allergic rhinitis, also called as hay fever, is actually an allergic response of the body due to certain allergens from the atmosphere around the patients. The most usual reason for the onset of allergic reactions is the large number of pollen in the environment. The mold, dust, and animal dander are some of the items that can produce allergic response. Allergic rhinitis causes symptoms such as constant sneezing, runny nose, watery eyes, and redness & swelling in the eyes. As per the World Allergy Organization (WAO) in 2012, the frequency of allergic rhinitis was around 1.5% to 40% in several countries in the world and nearly 75% of asthma patients were at risk of developing concomitant allergic rhinitis. This high prevalence and contributing factors such as asthma, respiratory diseases are driving the market in the near future.

Allergic rhinitis are categorized into three types, namely perennial, seasonal, or occupational rhinitis. Seasonal allergic rhinitis occurs in summer, spring, or early fall. It is caused due to the airborne mold pollens from grass, trees, and weeds. People with perennial allergic rhinitis suffer with year-round symptoms. The common stimulants are dust mites, cockroaches, pet hair or dander, or mold. Food allergies are also a cause for perennial nasal symptoms. Perennial allergic rhinitis is known as pollinosis. It goes unnoticed most of the times because as its symptoms are similar to the indications of common cold. It is the most frequent type of allergic rhinitis. The symptoms of the allergy are itching, congestion, sneezing, nasal obstruction, and rhinorrhea. The disease is identified by the use of tests such as allergen sensitivity test, blood test, skin test (patch test), radioallergosorbent testing, and skin prick test.

Market Trends, Drivers, Restraints, and Opportunities

• Growing incidences of asthma along with respiratory disorders is a key factor expected to propel the market growth during the projected period.
• Rising research and development initiatives towards the development of novel products as well as the strong pipeline of new products is boosting the market expansion.   
• Surge in awareness among the population regarding the allergies and increasing collaborations of companies are key factors for the market growth during the forecast period.
• Increase in patent expiration in the recent years is causing stiff competition among generic drugs developers. This is a major challenge restricting the market growth in the future.
• High cases of allergies along with increased awareness as well as changing lifestyles are offering huge opportunities for the market growth in the near future.

Scope of the Report

The report on the global perennial allergic rhinitis market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Anti-histamines segment is expected to grow at a rapid pace

Based on products, the global perennial allergic rhinitis market is divided into anti-histamines, steroids, decongestants, and others. The anti-histamines segment is anticipated to grow at a rapid pace during the forecast period owing to the high effectiveness of the drugs as well as highly preferred by the physicians. The anti-histamines drugs are diphenhydramine (Benadryl), fexofenadine (Allerga), and Loratadine (Claritin). The decongestants segment is a fast growing segment. It includes Sudafed and Afrin drugs.

The steroid segment, however, is anticipated to grow at significant pace in the coming years owing to the good results and fast response to the allergies. The products included in steroids are prednisolone, beclometasone (Beconase), Triamcinolone (Nasacort), Fluticasone (Nasonex), and triamcinolone acetonide. The others segment includes sodium cromoglycate, leukotriene receptor antagonists, and immunotherapy formulas desensitizing vaccines.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the projected period. This is attributed to the factors such as high cases in the region, great awareness among the population, high number of new products in the development, and well developed healthcare facilities. Furthermore, government initiatives is also driving the market in the region.

The Europe market is estimated to grow at a substantial pace in the coming years due to the new effective drug development in the market. The Xolair is a drug that is used in Europe market which has high penetration rate. Meanwhile, the Asia Pacific market is projected to hold a key market share during the targeted period owing to high population and governments’ policies in the region.

Segments

The global perennial allergic rhinitis market has been segmented on the basis of

Products

• Anti-histamines
• Decongestants
• Steroids
• Others

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Alcon Inc.
• Merck & Co. Inc.
• Biopharma
• Sumitomo Pharma Co.
• Genentech, Inc.
• Pfizer, Inc.
• Hanmi Pharmaceuticals, Inc.
• Hisamitsu Pharmaceutical Co.
• Teva Pharmaceutical Ltd.

Competitive Landscape

The key players in the global perennial allergic rhinitis market are Hanmi Pharmaceuticals, Inc.; Alcon Inc.; Merck & Co. Inc.; Genentech, Inc.; Pfizer, Inc.; Hisamitsu Pharmaceutical Co.; Biopharma; Sumitomo Pharma Co; and Teva Pharmaceutical Ltd.